Skip to main content
Premium Trial:

Request an Annual Quote

SV Bio Launched to Provide POC Genomic Data Services

NEW YORK (GenomeWeb News) – Silicon Valley Biosystems, a company that provides genomic data at the point of care, has been launched.

The Foster City, Calif.-based firm was launched today with financial backing from venture capital firm Sequoia Capital to provide turnkey genomics interpretation services to clinicians "to make faster, more precise, and cost-saving decisions," according to SV Bio.

Its services examine a patient's genome at the point of care to "distill the biological data into a concise, actionable report that medical generalists and specialists can easily use as a decision support tool," the company said. Services currently available include single genes and bundled gene sets for genetically heterogeneous diseases and diseases for which the causes are known.

Also, testing of the entire genome is available for illnesses where causative genes are unknown, or when a variant has been detected but can't be determined to be causative.

The SV Bio platform fits into current clinical workflows and can accept data from any next-generation sequencing platform to determine with clinical grade sensitivity and specificity the genetic variants within a patient's DNA sequence that influences a disease or condition, the company said. It added that it takes minutes to complete the sample sequence and deliver a report to a clinician.

"The transition is occurring very rapidly nowadays from genomics as a science to genomics as a key driver of clinical medicine and decision-making at the bedside," Dietrich Stephan, founder and CEO of SV Bio, said in a statement. "As genomic sequencing costs plummet, the potential clinical impact soars. SV Bio is building the requisite bridge from the genomics bench to the bedside, assisting physicians with the accurate and actionable interpretation they need for optimizing care for each individual."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.